Patents by Inventor Sergey Sikora

Sergey Sikora has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TROPONIN I AND SOLUBLE UROKINASE RECEPTOR DETECTION FOR DETERMINING THE RISK OF CARDIOVASCULAR DISEASE
    Publication number: 20190025328
    Abstract: Disclosed are systems and methods for detecting the sample concentration of cardiac troponin I (cTnI) and the sample concentration of soluble urokinase receptor (suPAR) to determine if a subject has or is at risk for developing cardiovascular disease or a complication of previously diagnosed cardiovascular disease.
    Type: Application
    Filed: October 27, 2016
    Publication date: January 24, 2019
    Applicants: ABBOTT LABORATORIES, EMORY UNIVERSITY, CARDIORISK LLC
    Inventors: Agim Beshiri, Arshed Ali Quyyumi, Sergey Sikora, Stephen Epstein
  • ISCHEMIC TOLERANT CELLS AND CELLULAR FACTORS IN THE TREATMENT OF PERIPHERAL ARTERY DISEASE
    Publication number: 20160287638
    Abstract: A method for treatment of peripheral arterial disease conditions comprising systemically administering an effective amount of therapeutic stem cells. Included within the scope of the invention is intravenous administration of a therapeutic amount of ischemic tolerant mesenchymal stem cells in the treatment of peripheral arterial disease.
    Type: Application
    Filed: April 2, 2015
    Publication date: October 6, 2016
    Applicant: Stemedica Cell Technologies, Inc.
    Inventors: Stephen E. Epstein, Alex Kharazi, Nikolai Tankovich, Sergey Sikora
  • DIAGNOSTIC ASSAY TO PREDICT CARDIOVASCULAR RISK
    Publication number: 20140350129
    Abstract: This invention relates to the area of cardiovascular disorders and specifically relates to methods of diagnostic tests using a combination of markers to predict an individual's risk for developing coronary artery disease (CAD) and related diseases, such as angina pectoris and peripheral vascular disease and, more particularly, to determine an individual's risk of myocardial infarction, death, and stroke. Exemplary biomarkers include C-reactive protein (CRP), fibrin degradation products (FDPs), Heat Shock Protein 70 (HSP70), and/or anti-CMV antibody.
    Type: Application
    Filed: March 1, 2012
    Publication date: November 27, 2014
    Applicants: Genway Biotech, Inc., Emory University, Medstar Health Research Institute
    Inventors: Sergey Sikora, Stephen Epstein, Arshed A. Quyyumi
  • Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMP-dependent kinase and a target for SARS therapy
    Patent number: 7504205
    Abstract: The present invention relates to novel methods for identifying antiviral agents which selectively interfere with viral proteins that cause the unique infectivity activity of the SARS-coronavirus in comparison to other non-SARS strains of coronavirus. In particular, the present invention relates to screening assays that identify agents which selectively inhibit cyclic-AMP dependent protein kinase activity of the SARS-coronavirus ORF3. The present invention also relates to screening assays that identify agents which selectively inhibit the interaction between SARS-coronavirus cyclic-AMP dependent protein kinase and a calcium dependent targeting molecule. Therefore the agents identified using the assays of the invention may have utility as antiviral agents. The present invention also relates to treatments for sever acute respiratory syndrome caused by a coronavirus, and particularly to treatments that affect the infectivity activity of the SARS-coronavirus.
    Type: Grant
    Filed: May 17, 2005
    Date of Patent: March 17, 2009
    Assignee: The Burnham Institute
    Inventors: Adam Godzik, Sergey Sikora
  • Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMP-dependent kinase and a target for SARS therapy
    Publication number: 20050276818
    Abstract: The present invention relates to novel methods for identifying antiviral agents which selectively interfere with viral proteins that cause the unique infectivity activity of the SARS-coronavirus in comparison to other non-SARS strains of coronavirus. In particular, the present invention relates to screening assays that identify agents which selectively inhibit cyclic-AMP dependent protein kinase activity of the SARS-coronavirus ORF3. The present invention also relates to screening assays that identify agents which selectively inhibit the interaction between SARS-coronavirus cyclic-AMP dependent protein kinase and a calcium dependent targeting molecule. Therefore the agents identified using the assays of the invention may have utility as antiviral agents. The present invention also relates to treatments for sever acute respiratory syndrome caused by a coronavirus, and particularly to treatments that affect the infectivity activity of the SARS-coronavirus.
    Type: Application
    Filed: May 17, 2005
    Publication date: December 15, 2005
    Inventors: Adam Godzik, Sergey Sikora